The global cancer diagnostics market size was valued at USD 112.6 billion in 2025 and is projected to grow from USD 119.25 billion in 2026 to USD 188.79 billion by 2034, registering a CAGR of 5.91% during the forecast period from 2026 to 2034. North America dominated the cancer diagnostics market with a market share of 39.5% in 2025.
Cancer diagnostics refers to the medical tests, technologies, and procedures used to detect, identify, characterize, and monitor cancer. It includes imaging techniques, biopsy and pathology tests, molecular diagnostics, biomarker testing, liquid biopsy, and other diagnostic methods used to determine the presence and characteristics of tumors. Cancer diagnostics supports early detection, accurate diagnosis, disease monitoring, treatment selection, and personalized cancer care.
Download a Free Sample To learn more about this report,
Growing Adoption of Multi-Cancer Blood Testing
The cancer diagnostics market is increasingly moving toward blood-based tests designed to identify signals associated with several cancers from a single sample. These assays analyze circulating molecular information and can complement conventional organ-specific screening by providing a broader approach to early detection. Their development is particularly important for cancers that currently lack routine population screening pathways. Multi-cancer blood testing is therefore becoming an important part of cancer diagnostics market trends.
In June 2026, GRAIL expanded its Galleri multi-cancer early detection program following analysis involving more than 25,000 participants. The blood test is designed to detect signals associated with more than 50 cancer types and predict the cancer signal's tissue of origin.
Increasing Integration of AI Into Digital Pathology
Pathology laboratories are increasingly combining digitized tissue slides with artificial intelligence to support cancer detection and grading. AI algorithms can identify suspicious regions, quantify tissue characteristics, and prioritize slides for review while pathologists retain responsibility for diagnosis. This approach can reduce repetitive visual assessment and help standardize interpretation across large case volumes. AI-assisted pathology is consequently expanding the cancer diagnostics industry toward computational tissue analysis.
In March 2025, Paige received regulatory authorization for an AI application supporting prostate-cancer pathology. The technology was developed using a dataset containing more than 3 million digitized pathology slides to support AI-based cancer assessment.
Expansion of Precision Oncology Increases Biomarker Testing Requirements
Cancer treatment is increasingly determined by specific molecular characteristics rather than tumor location alone. Clinicians therefore need diagnostic tests capable of identifying mutations, gene fusions, expression patterns, and other biomarkers before selecting targeted therapies. As the number of biomarker-linked medicines increases, molecular testing becomes a more routine component of cancer diagnosis and treatment planning. Precision medicine is therefore strengthening cancer diagnostics market demand.
In May 2026, Foundation Medicine expanded FoundationOne Liquid CDx with additional biomarker and therapy-related capabilities. The blood-based comprehensive genomic profiling test evaluates more than 300 cancer-related genes from circulating tumor DNA.
High Cost of Advanced Molecular Testing Can Limit Patient Access
Comprehensive genomic profiling, liquid biopsy, and other advanced diagnostic methods require sophisticated sequencing platforms, specialized reagents, bioinformatics infrastructure, and trained laboratory personnel. Testing costs can therefore remain substantially higher than conventional histology or basic biomarker assays. Limited reimbursement can further discourage routine use when the clinical benefit is uncertain for a specific patient. Affordability can consequently restrain cancer diagnostics market growth.
In August 2025, Guardant Health expanded patient-access programs for its advanced oncology testing portfolio, including Guardant360 CDx, which analyzes 74 genes, reflecting continued industry efforts to address access and affordability around comprehensive molecular diagnostics.
Expansion of Minimal Residual Disease Testing
Minimal residual disease testing provides a distinct opportunity by detecting traces of cancer that may remain after surgery or other treatment even when conventional imaging shows no visible disease. Circulating tumor DNA can help identify patients at greater risk of recurrence and support decisions about additional therapy or closer surveillance. This extends diagnostics from initial cancer identification into post-treatment disease monitoring. MRD testing can therefore help providers increase cancer diagnostics market share.
In January 2026, Natera expanded clinical use of Signatera for molecular residual disease assessment. The personalized test tracks up to 16 patient-specific tumor mutations in circulating tumor DNA to identify residual or recurrent disease after treatment.
Obtaining Adequate Tumor Material for Reliable Testing
Many patients have small tumors, inaccessible lesions, or biopsy samples containing limited quantities of malignant tissue. Repeated invasive biopsies can also be difficult when disease progresses or treatment decisions require updated molecular information. Insufficient material can prevent complete testing or produce inconclusive results, forcing laboratories to balance analytical sensitivity with limited sample availability. Sample adequacy therefore remains a major challenge as cancer diagnostics market size expands toward increasingly detailed molecular analysis.
In October 2025, Tempus AI expanded its xF liquid-biopsy testing capabilities for patients where tissue availability is limited. The assay analyzes circulating tumor DNA across more than 100 genes, providing an alternative molecular-testing pathway when obtaining sufficient tumor tissue is difficult.
Consumables Segment Dominated the Market with 63.7% Share in 2025
The consumables segment dominated the global cancer diagnostics market with a 63.7% share in 2025, driven by the recurring requirement for reagents, test kits, assay components, and other disposable materials used in cancer screening, diagnosis, and monitoring. Increasing adoption of laboratory-based testing and growing demand for accurate and timely cancer detection continue to support the segment's leading position.
The instruments segment supports cancer diagnosis through equipment used for sample analysis, molecular testing, imaging, and other diagnostic procedures. Increasing adoption of automated and technologically advanced diagnostic systems is supporting demand for sophisticated instruments across hospitals, laboratories, and other healthcare settings.
Request Customizationto receive a tailored report.
Lung Cancer Segment is Projected to Register the Fastest Growth at a CAGR of 8.16%
The lung cancer segment is projected to register the fastest growth at a CAGR of 8.16% during 2026–2034, driven by increasing emphasis on early detection, screening, molecular diagnostics, and improved disease monitoring. Growing awareness of lung cancer risks and advances in diagnostic technologies are encouraging the adoption of more precise testing solutions.
The breast cancer segment represents a major application due to widespread screening and diagnostic testing requirements. Colorectal cancer diagnostics support early detection and disease monitoring, while cervical cancer diagnostics remain important for preventive screening. Prostate, skin, blood, kidney, liver, pancreatic, and ovarian cancer applications contribute through specialized screening, diagnosis, and monitoring requirements.
Hospitals and Clinics Segment Dominated the Market with 44.6% Share in 2025
The hospitals and clinics segment dominated the global cancer diagnostics market with a 44.6% share in 2025, supported by the high volume of cancer screening, diagnostic testing, treatment planning, and disease monitoring procedures performed in clinical settings. The availability of specialized healthcare professionals and diagnostic infrastructure continues to support the segment's leading position.
The diagnostic laboratories segment is gaining traction due to increasing demand for specialized testing, molecular diagnostics, and outsourced laboratory services. Diagnostic imaging centers support cancer detection and evaluation through advanced imaging procedures, while research institutes contribute to the development and validation of emerging diagnostic technologies, biomarkers, and testing approaches.
Speak to an Analystto discuss market opportunities.
The North American cancer diagnostics market accounted for 39.5% of the global market, reaching USD 44.48 billion in 2025. The region holds the largest market share, supported by advanced healthcare infrastructure, widespread availability of diagnostic technologies, high healthcare expenditure, and strong adoption of molecular, imaging, and laboratory-based cancer diagnostic solutions.
The United States represents a major market in North America. Advanced diagnostic infrastructure, high adoption of precision medicine, extensive cancer screening programs, and increasing use of molecular and imaging technologies continue to support market growth.
Canada's developed healthcare infrastructure, expanding cancer screening initiatives, and increasing adoption of advanced diagnostic technologies continue to support cancer diagnostics market development.
Unlock Regional Insightsto access country-level data, & regional trends.
The European cancer diagnostics market accounted for 28.4% of the global market, reaching USD 31.98 billion in 2025, and is projected to grow at the fastest CAGR of 8.21% during the forecast period. Increasing cancer incidence, expanding screening programs, improvements in diagnostic technologies, and growing adoption of precision medicine are supporting regional market expansion.
Germany represents a major European market. Its advanced healthcare infrastructure, established cancer screening programs, and strong adoption of molecular and imaging diagnostics continue to support market development.
The United Kingdom's established healthcare system, cancer screening initiatives, and increasing adoption of advanced diagnostic technologies continue to create opportunities for cancer diagnostics market growth.
The Asia Pacific cancer diagnostics market accounted for 22.6% of the global market, reaching USD 25.45 billion in 2025, and is expected to grow at a CAGR of 7.86% during the forecast period. Rising cancer prevalence, improving healthcare infrastructure, increasing healthcare expenditure, and expanding access to advanced diagnostic technologies are driving regional market growth.
China represents a major market within the Asia Pacific. Growing cancer screening requirements, expanding hospital infrastructure, and increasing adoption of molecular and imaging-based diagnostics continue to support market development.
Japan's advanced healthcare infrastructure, aging population, established cancer screening programs, and adoption of precision diagnostic technologies continue to support cancer diagnostics demand.
India's expanding healthcare infrastructure, increasing cancer awareness, growing diagnostic capacity, and rising adoption of advanced testing technologies continue to create opportunities for market growth.
Latin America's cancer diagnostics market accounted for 5.7% of the global market, reaching USD 6.42 billion in 2025, and is projected to grow at a CAGR of 6.48% during the forecast period. Improving healthcare infrastructure, increasing cancer awareness, expanding screening programs, and growing access to diagnostic technologies are supporting regional market development.
Brazil represents a major regional market. Its expanding healthcare infrastructure, growing diagnostic networks, and increasing focus on cancer screening and early detection continue to support market growth.
The Middle East & Africa cancer diagnostics market accounted for 3.8% of the global market, reaching USD 4.28 billion in 2025, and is anticipated to grow at a CAGR of 5.94% during the forecast period. Healthcare infrastructure development, increasing cancer awareness, and improving access to screening and diagnostic services are supporting regional market growth.
The UAE's advanced healthcare infrastructure, increasing investment in specialized medical services, and growing focus on early cancer detection continue to create opportunities for cancer diagnostics market development.
Saudi Arabia's healthcare modernization, expanding diagnostic infrastructure, and increasing emphasis on cancer screening and early detection continue to support cancer diagnostics market growth.
The global cancer diagnostics market is highly competitive, with leading diagnostics, medical technology, life sciences, imaging, and biotechnology companies competing through in vitro diagnostics, molecular diagnostics, pathology, imaging systems, biomarker testing, companion diagnostics, and cancer screening solutions. The major players in the market include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, GE HealthCare, Hologic Inc., Koninklijke Philips N.V. (Philips Healthcare), QIAGEN N.V., Roche Holdings AG (F. Hoffmann-La Roche Ltd.), Siemens Healthineers, Thermo Fisher Scientific Inc., and others.
Industry participants are focusing on developing more sensitive, rapid, and personalized diagnostic solutions for cancer detection, screening, diagnosis, treatment selection, and disease monitoring. Companies are investing in molecular diagnostics, next-generation sequencing, liquid biopsy, companion diagnostics, digital pathology, artificial intelligence, advanced imaging, and multi-cancer detection technologies. Increasing cancer incidence, demand for earlier diagnosis, expansion of precision oncology, improvements in biomarker testing, and growing adoption of minimally invasive diagnostic technologies are driving competition across the market.
Abbott Laboratories is a major global healthcare and diagnostics company with an expanding presence across the cancer diagnostics landscape. Its portfolio includes cancer screening, precision oncology, molecular diagnostics, and diagnostic testing solutions spanning different stages of the cancer care continuum. Abbott has expanded its oncology capabilities through technologies including Cologuard, Oncotype DX, Cancerguard, and Oncodetect.
These developments strengthen Abbott's capabilities across early detection, screening, precision oncology, and recurrence monitoring, reinforcing its competitive position in the global cancer diagnostics market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Amniotic Membrane Market Size, Share, Growth, Forecast, 2034
3D Bioprinting Market Size, Share, Growth, Analysis, Report, 2034
Mass Spectrometry Market Size, Share, Growth, Analysis, 2034
Cancer Biomarker Market Size, Share, Growth, Forecast, 2034
Biomaterials Market Size, Share, Growth, Analysis, Report, 2034
CRISPR Gene Editing Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com